Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Alexander B. Philipp"'
Autor:
Rainer W. J. Kaiser, Julian Allgeier, Alexander B. Philipp, Julia Mayerle, Camilla Rothe, Claudia Wallrauch, Mark op den Winkel
Publikováno v:
BMC Gastroenterology, Vol 20, Iss 1, Pp 1-8 (2020)
Abstract Background Infection with Entamoeba histolytica and associated complications are relatively rare in developed countries. The overall low prevalence in the Western world as well as the possibly prolonged latency period between infection with
Externí odkaz:
https://doaj.org/article/9921ee8a36314a6fa5f51ae167785c95
Autor:
Enrico De Toni, Dorothea Nagel, Alexander B. Philipp, Andreas Herbst, Isabel Thalhammer, Julia Mayerle, Helga-Paula Török, Lydia Brandl, Frank T. Kolligs
Publikováno v:
Cellular Physiology and Biochemistry, Vol 45, Iss 2, Pp 605-613 (2018)
Background/Aims: Osteoprotegerin (OPG) is a soluble receptor of the pro-apoptotic cytokine TRAIL which is thought to contribute to tumour development by inhibiting apoptosis or affecting other aspects of tumour biology, including cell proliferation a
Externí odkaz:
https://doaj.org/article/5b3df91f98c74a4ca00222633b68895c
Autor:
Daniel Roessler, Osman Öcal, Alexander B. Philipp, Daniel Markwardt, Stefan Munker, Julia Mayerle, Leonie S. Jochheim, Katharina Hammer, Christian M. Lange, Andreas Geier, Max Seidensticker, Florian P. Reiter, Enrico N. De Toni, Najib Ben Khaled
Publikováno v:
Journal of cancer research and clinical oncology.
Introduction Immune checkpoint inhibitor (ICI)-based regimens are transforming the landscape of hepatocellular carcinoma (HCC) treatment. We describe the effect of combined ipilimumab and nivolumab in patients with advanced HCC after the failure of p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e682aed3a90c212681b1f24d4c9b23f3
https://pubmed.ncbi.nlm.nih.gov/35864269
https://pubmed.ncbi.nlm.nih.gov/35864269
Autor:
Catherine Leyh, Ursula Ehmer, Daniel Roessler, Alexander B. Philipp, Florian P. Reiter, Petia Jeliazkova, Leonie S. Jochheim, Matthias Jeschke, Janina Hammig, Johannes M. Ludwig, Jens M. Theysohn, Andreas Geier, Christian M. Lange
Publikováno v:
Cancers; Volume 14; Issue 8; Pages: 1975
The optimal treatment sequence of tyrosine kinase inhibitor (TKI)-based therapy in patients with hepatocellular carcinoma (HCC) remains unclear. Therefore, sequential systemic therapy after first-line therapy with sorafenib or lenvatinib was compared
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5a97175dbe22d4985b687a612e973b2
https://www.ncbi.nlm.nih.gov/pubmed/35454881
https://www.ncbi.nlm.nih.gov/pubmed/35454881
